-
Resiquimod (R-848) in Tumor Immunology Workflows
2026-08-16
Resiquimod (R-848) provides a practical way to activate TLR7/8 and connect innate immune response modulation with cytokine, dendritic-cell, and macrophage assays. In advanced tumor-ablation research, its combination with responsive hydrogel delivery illustrates how localized immune stimulation can complement thermal treatment while limiting formulation and assay artifacts.
-
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-08-15
Masitinib (AB1010), SKU A2942, is a DMSO-soluble research inhibitor for experiments centered on KIT, PDGFRα, PDGFRβ, mast cell responses, and selected mutant KIT models. It is not appropriate for protocols requiring aqueous or ethanol solubility, broad-spectrum kinase inhibition, or direct clinical translation without additional evidence.
-
DAPI Workflow for iMSC–NP Cell Assays
2026-08-15
Build reproducible nuclear imaging, apoptosis, and viability workflows with DAPI Solution (1 mg/mL), from fixed nucleus pulposus cultures to flow cytometry. The approach translates a recent iMSC-exosome study into practical controls, acquisition choices, and troubleshooting decisions for intervertebral disc degeneration research.
-
JAK Inhibitors and Endothelial Cardiovascular Effects
2026-08-14
A 2025 ACR Open Rheumatology study compared six JAK inhibitors in cytokine-stimulated human endothelial cells and showed that suppressing IL-6 does not uniformly normalize adhesion, coagulation, or cell-death responses. The findings support a pathway- and dose-aware interpretation of vascular effects rather than treating all JAK inhibitors as pharmacologically equivalent.
-
Sulfamonomethoxine: Applied Research Workflows
2026-08-14
Sulfamonomethoxine (SMM) is a practical DHPS-targeting tool for bacterial, veterinary, aquaculture, and environmental research. This guide converts its solubility limits and mixed antiprotozoal performance into reproducible assay workflows, controls, and troubleshooting decisions.
-
Triacetin: Mechanism-to-Assay Research Guide
2026-08-13
Triacetin and glyceryl triacetate can function as more than a solvent: they offer a context-sensitive probe for metabolic, epigenetic, and cancer biology. This guide connects mechanism, assay design, dose interpretation, and pharmacogenomic thinking without overstating experimental evidence.
-
Coronavirus Macrodomains and PARP-Mediated Antiviral Defense
2026-08-13
The reference study shows that a coronavirus macrodomain protects viral replication by counteracting PARP-dependent antiviral and interferon responses. Its combination of viral genetics, pharmacological inhibition, and PARP12/PARP14 knockdown provides a mechanistic framework for studying ADP-ribosylation in host–virus interactions.
-
Fe3O4@ZIF-8 for Jaw Osteomyelitis
2026-08-12
The reference study presents Fe3O4@ZIF-8 core–shell nanoparticles as a dual-function platform for treating jaw osteomyelitis, combining acid-responsive antibacterial activity with magnetic-field-assisted bone regeneration. Its mechanistic contribution is the proposed link between Zn2+-mediated membrane and heat-shock disruption, bacterial death, and subsequent Fe3O4-associated osteogenesis.
-
JXE-23 Induces Protective Autophagy in HCC Cells
2026-08-12
The 2024 reference study identifies JXE-23, a pimarane-type diterpene from Aleuritopteris albofusca, as a selective inhibitor of HepG2 hepatocellular carcinoma cell growth. Its combination of G2/M arrest, migration suppression, and protective autophagy induction links the CIP2A/p-AKT/c-Myc axis to a potentially exploitable survival response.
-
PBA-Modified PAD4 Inhibitors Target Tumor NETs
2026-08-11
The reference study developed phenylboronic acid-modified PAD4 inhibitors to preferentially target tumor-associated environments while suppressing the PAD4–H3cit–NET pathway in neutrophils. Its lead compound, 5i, limited tumor growth and lung metastasis in mouse models primarily through an anti-metastatic, immune-microenvironment mechanism rather than direct tumor-cell killing.
-
Phenacetin for Reproducible PK Assay Workflows
2026-08-10
Phenacetin provides a chemically defined, poorly water-soluble probe for stress-testing dissolution, dosing, and analytical recovery in cell-based pharmacokinetic workflows. This guide combines practical stock preparation, organoid-compatible exposure strategies, troubleshooting, and a careful translation of PDK4 inhibitor discovery principles into assay design.
-
Light-Controlled RNA Release for Gene Therapy
2026-08-09
A 2026 Trends in Biotechnology study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that suppresses mRNA translation in darkness and permits transgene expression under blue or ambient light. The platform regulated therapeutic programs in mouse models of diet-induced obesity and retinal neovascular disease, illustrating how optical control could add reversibility and timing control to gene therapy.
-
FPH1 (BRD-6125): From Expansion to Assay Design
2026-08-08
FPH1 (BRD-6125) is examined here as a temporal assay-design tool rather than simply a proliferation enhancer. This guide connects functional hepatocyte expansion, iPSC-derived hepatocyte maturation, and light-regulated gene-expression concepts while defining practical controls and limitations.
-
ABT-199: Mapping BCL-2-Dependent Apoptosis
2026-08-07
ABT-199, also known as Venetoclax, is examined here as a precision tool for mapping mitochondrial apoptosis rather than simply as a cytotoxic reagent. Learn how selective BCL-2 inhibition, BH3 profiling, and orthogonal apoptosis assays can reveal therapeutic dependencies and resistance mechanisms.
-
Recombinant Human FGF-19: Unveiling Metabolic Regulation in
2026-08-07
Explore the pivotal role of Recombinant Human FGF-19 in metabolic regulation and acute kidney injury (AKI) research. This in-depth article reveals novel cross-talk between endocrine signaling and p38 MAPK pathways, providing advanced assay guidance for translational scientists.
454 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page